The global CRISPR Gene Editing Market was valued at USD 1.09 billion in 2021 and is predicted to reach USD 14.80 billion by 2030, increasing at a CAGR of 29.80% from 2022 to 2030. Gene editing, also known as genome editing, is a technique for altering an organism's DNA using a variety of methods. This approach allows for the replacement, addition, or removal of genetic material at spotted places in the genome. As a result, a variety of editing techniques have been created for its use in the industry. Human disorders such as cystic fibrosis, sickle cell disease, HIV infection, cancer, and others are also treated and prevented through gene editing.
Genome engineering has had a significant impact on the future of the healthcare and life science industries, as evidenced by its progress. The remarkable efficiency of the CRISPR-Cas9 method for genome editing has been established in much research, leading to considerable investments in the field of genome engineering. Prior to any clinical use, it is necessary to weigh the benefits and drawbacks of each potential variant. CRISPR gene editing technique has its limitations, and many researchers are attempting to overcome them in order to get better outcomes. Incredibly, the CRISPR gene editing technology holds enormous promise for modifying human genomes and disease conditions. However, ethical and societal problems abound.
Research organizations, pharmaceutical, and biotechnology firms, and institutions are seeking more efficient genome editing tools to increase specificity, cost-effectiveness, turnaround speed, and human errors. Genome editing methods have evolved to enable applications in industrial biotech and agricultural research. These new technologies are simple, efficient, cost-effective, multiplex, and high throughput. The increasing geriatric population, cancer cases, and genetic abnormalities will boost the demand for CRISPR gene editing.
Get more information on this report Download Sample Report
The growth of the CRISPR gene editing business will be fueled by increased financing for genetic research in industrialized areas like North America. Many governmental agencies in the United States invested in the creation of new materials, equipment, and processes for the benefit of the public good. Government funding helps to develop and manufacture medical discoveries for rare genetic illnesses. Funding for genomics research is provided by the National Human Genome Research Institute (NHGRI).
Genetic and biological research is carried out by the National Institutes of Health (NIH), an agency of the Department of Health and Human Services and a medical research organization in the United States. Arizona State University and Bayer College of Medicine will get USD 1.6 million from the NIH in 2021 to test human genome editing. It is expected that the CRISPR gene editing market growth will be boosted by the development of new treatments for genetic diseases.
When it comes to chronic illnesses, one in three persons suffer from one or more. Many people's health and well-being have been adversely affected by chronic diseases. Clustered regularly interspaced short palindromic repeats (CRISPR) is the abbreviation for this technology. Using CRISPR, a gene-editing technique has become a powerful tool in recent years. Huntington's disease, muscular dystrophy, cancer, and excessive cholesterol all benefit from CRISPR. Consider, for example, the diagnosis rate for Duchenne Muscular Dystrophy in 2021 as reported by NORD - the National Organization for Rare Disorders, Inc. (DMD). Every 3,500 male babies around the world are born with the hereditary disorder known as Duchenne Muscular Dystrophy (DMD). In addition, factors like as rising disposable income, an increasing prevalence of chronic diseases, and alterations in lifestyle will all contribute to the expansion of the global CRISPR gene editing market.
There is a high price to pay for CRISPR-based therapies. Due to the increased time and resources required for the research and production of maximum genome editing medicines, the cost rises. In addition, a wide range of people can benefit from CRISPR gene detection and diagnostic assay kits and treatments. Patients are forced to bear the burden of these expenses. As a result, a decline in the current high price is projected in the future. For example, the first commercially accessible CRISPR-based diagnostic assay for SARS-CoV-2, comprising reverse transcription LAMP (RT-LAMP) as pre-amplification, will be available in July 2021 at USD 30.15 per response, according to Integrated DNA Technologies, Inc. The Global CRISPR Gene Editing Market is expected to experience slow growth over the next few years due to ethical concerns about genetic editings, such as safety and the high cost of gene treatments.
The market is divided into contract research organizations (CROs), biotechnology and pharmaceutical businesses, and research institutes according to the type of end-user they serve. In 2021, the segment consisting of biotech and pharmaceutical companies held more than 45.5 percent of the market share. The segmental expansion will be increased as a result of an increasing focus on the development of novel gene editing methods by a variety of biotechnology companies. For example, Horizon Discovery's goal was to develop a genome editing tool that utilized cutting-edge technology to produce functional genes that were both precise and effective. The company has released a number of products, one of which is the Modify-R algorithm CRISPR guide RNAs, which can edit the gene that is being targeted. Over the course of the past several years, developments in technology have made it possible for market participants to develop gene editing tools that are effective for the treatment of genetic illnesses.
The Global CRISPR Gene Editing Market share is divided into different segments according to Product Type, Application, End-User, and Geography.
By Product Type, the Global CRISPR Gene Editing Market is segmented into CRISPR Products and Services. CRISPR Products are further divided into Kits and Enzymes (Vector-Based Cas9, and DNA-Free Cas9), Libraries, Design Tools, Antibodies, and Other Products (CRISPR/Cas9 plasmids, CRISPR Controls, and CRISPR RNAs). CRISPR Services are further divided into gRNA Design and Vector Construction, Cell Line and Engineering, Screening Services, and Other Services (Mediated Transcriptome Editing, and Epigenome Editing Services).
By Application, the Global CRISPR Gene Editing Market is segmented into Agricultural, Biomedical (which include Gene Therapy, Drug Discovery, And Diagnostics), Industrial, and Other Applications such as Genetically Modified Foods (GM Foods), Biofuel, And Animal (Livestock) Breeding.
By End-User, the Global CRISPR Gene Editing Market is segmented into Academic Institutes and Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), and Pharmaceutical and Biopharmaceutical Companies. Biotechnology Companies and Pharmaceutical and Biopharmaceutical Companies are the most important End-User segments among all others.
By Geography, the Global CRISPR Gene Editing Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global share because of significant investments by pharmaceutical and biotech organizations, improved healthcare infrastructure, rising per capita income, early availability of approved therapies, and the presence of state-of-the-art research labs and institutions in the region.
Regional Growth Insights Request Sample Pages
The Global CRISPR Gene Editing Market share is segmented by geography into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global share of the CRISPR gene editing market because of significant investments by pharmaceutical and biotech organizations, improved healthcare infrastructure, rising per capita income, early availability of approved therapies, and the presence of state-of-the-art research labs and institutions in the region. Because to the rise in rare illnesses in the United States and Canada, North America accounted for roughly 38% of the market in 2021 and is predicted to grow significantly throughout the forecast years. Approximately 7,000 uncommon diseases impact between 25 and 30 million Americans, according to the National Institutes of Health (NIH). As a result, as new gene editing tools and technologies become available, the demand for medication development to treat rare disorders grows.
Due to major advances in drug discovery analysis, an expansion in the number of research studies, the growth of the biotech industry, and other factors, the United States has risen to the top of the market.
North America is expected to have the greatest market share in 2030. The rise in government and private funding, the existence of big pharma and gene therapy businesses, and the use of CRISPR in a variety of applications are all contributing to this. Furthermore, crops treated with CRISPR-based gene editing are not deemed GMOs in the United States, which has prompted a number of agricultural companies to work on CRISPR-edited crop commercialization.
The Asia Pacific CRISPR gene editing market was valued at approximately 1.1 billion USD in 2021. An increasing number of research organizations in emerging countries will contribute to an improved industry landscape in the region. Growth in the regional sector is expected to be fueled by the major corporations' current focus on the development of gene editing technology. The market for bioscience is experiencing the most rapid expansion in the Asia Pacific region. This occurs as a result of the increased financing provided by the government to the biotechnology industry for the purpose of enhancing disease treatment. The growth of research and development efforts in China, Japan, and India will also play a role in driving regional market trends.
Due to a lack of technical understanding, the expansion of the CRISPR Gene Editing Market will be hampered by the limited development in the biotechnology sector that has occurred in both the Middle East and Africa